Paris, France and Manchester, UK – 19 May 2026 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the launch of Yourgene® Insight DPYD assay, an assay utilizing genetic Insights for safer chemotherapy treatments to align with updated testing guidelines.
Yourgene® Insight DPYD is a simple-to-use genotyping test that can identify cancer patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency, which can cause severe and sometimes lethal side effects in patients being treated with chemotherapeutic drug 5-Fluorouracil (5-FU), commonly used in the treatment of colorectal, head and neck, breast, pancreatic and stomach cancers. Over two million cancer patients globally are treated with fluoropyrimidines (including 5-FU) each year; 10-20% of these patients suffer severe, and sometimes fatal side effects associated with DPD deficiency. Screening patients for DPYD variants allows treatments to be adjusted accordingly.
Following updated guidelines from a joint consensus of organisations such as AMP (Association for Molecular Pathology) and ACMG (American College of Medical Genetics and Genomics), the 2019 original Yourgene® DPYD test has been enhanced to enable the number of variants to be detected to increase from six to 19, including the 14 recommended by these updated guidelines, demonstrating the Company’s ability to meet customer and market needs. The product has been launched for Research Use Only (RUO) initially with In Vitro Diagnostic Regulation (IVDR) and other regulatory territory approvals to follow in due course. Many countries have already implemented DPYD genotyping ahead of prescribing chemotherapy treatment and there is a mixed model of private pay and reimbursement.
The Yourgene® Insight DPYD test has the same workflow and format as the original DPYD kit, with ready-to-use reagents, simple data interpretation to identify the presence or absence of 19 variants and a fast turnaround time enabling results to be provided the same day, ensuring there is no delay in patients starting their chemotherapy treatment.
The Company has continued to invest in research and development to expand its product portfolio, and it is encouraging to see this investment translating into commercially launched products and tangible pipeline progress.
Lyn Rees, Chief Executive Officer of Novacyt, commented: “We are pleased to have launched the Yourgene® Insight DPYD assay on schedule, enabling a streamlined, cost-effective pharmacogenetic workflow that supports safer, more personalised treatment decisions for cancer patients at risk of suffering a severe, and potentially life-threatening reaction to common chemotherapy. By listening to customer feedback and working with key opinion leaders, we have ensured additional variants have been included in the test enhancing our global coverage for the product, strengthening our market position. The new kit delivers a deeper insight and greater confidence for clinical decision-making, helping reduce adverse side effects while improving patient safety.”
Contacts
|
Novacyt SA |
||||
|
Lyn Rees, Chief Executive Officer |
Via Walbrook PR |
|||
|
Steve Gibson, Chief Financial Officer |
||||
